selected scholarly activity
-
conferences
- EP102: Pharmacological Inhibition of METTL3 Elicits Tumor Growth Inhibition In Vivo and Demonstrates Synergy with Venetoclax in Various AML Models. Blood. 2263-2263. 2023
- Abstract 6282: EP102: Pharmacological inhibition of METTL3 arrests tumor progression and prolongs survival in CDX and PDX models of AML. Cancer Research. 6282-6282. 2023
- Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma. 3188-3197. 2020
- The Neurokinin 3 Receptor Antagonist, Fezolinetant, is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study. Journal of Women's Health. 15-15. 2019
- FACTs Fabry gene therapy clinical trial: Two-year data. Molecular Genetics and Metabolism. S99-S99. 2019
- Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study. Blood. 5548-5548. 2018
- Does Modern Mediastinal Irradiation Cause Acute Subclinical Cardiac Toxicity? The Final Results of the MEDICATE Study (Mediastinal Irradiation and Cardio-Toxic Effects). International Journal of Radiation Oncology Biology Physics. S88-S89. 2018
- Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis. Blood. 2017
- Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL - Results from Multicenter Phase II Trial CLL-009. Blood. 2017
- Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. Oncology Research and Treatment. 34-35. 2017
- 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. Blood. 2042-2042. 2016
- Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. Blood. 4403-4403. 2016
- Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. Oncology Research and Treatment. 34-35. 2016
- IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY. Haematologica. 150-151. 2016
- Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.. Journal of Clinical Oncology. 7525-7525. 2016
- Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials. Blood. 2944-2944. 2015
- Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue. Blood. 267-267. 2015
- Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial. Blood. 1732-1732. 2015
- Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood. 2938-2938. 2015
- Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. Blood. 2936-2936. 2015
- Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial. Leukemia and Lymphoma. 93-94. 2015
- Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial. Leukemia and Lymphoma. 98-100. 2015
- Ibrutinib combined with bendamustine/rituximab (BR) in previously treated small lymphocytic lymphoma (SLL): analysis of patients in the HELIOS trial. Leukemia and Lymphoma. 92-93. 2015
- Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.. Journal of Clinical Oncology. LBA7005-LBA7005. 2015
- IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY. Haematologica. 55-56. 2015
- Intake of Soy Isoflavones Reduces Breast Cancer Incidence among Women in North America. The FASEB Journal. 2015
- A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193. Blood. 5670-5670. 2014
- A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas.. Journal of Clinical Oncology. 8551-8551. 2014
- Health Care Resource Utilization in the Management of Chronic Lymphocytic Leukemia at an Ontario Cancer Centre. Value in Health. A79-A79. 2014
- TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). Blood. 1638-1638. 2013
- VEGETARIAN DIETARY PATTERNS ASSOCIATED WITH BIOMARKERS OF CANCER RISK. American Journal of Epidemiology. S110-S110. 2013
- DOSE-ESCALATION AND PHARMACOKINETICS (PK) OF DIFFERENT LENALIDOMIDE (LEN) STARTING DOSE REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY (REL/REF) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (CC-5013-CLL-009). Haematologica. 41-42. 2013
- Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario.. Journal of Clinical Oncology. 2013
- IDENTIFYING THE HEALTH AND SUPPORTIVE CARE NEEDS OF ADOLESCENT AND YOUNG ADULT CANCER PATIENTS AND SURVIVORS. Pediatric Blood and Cancer. 1119-1119. 2012
- Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non-Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. Blood. 917-917. 2011
- Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study). Blood. 1233-1233. 2011
- Identifying the Health Care Supportive needs of Adolescents and Young Adult Cancer Patients and Survivors: Preliminary Findings from a Qualitative Study. International Journal of Qualitative Methods. 481-482. 2011
- INITIAL OUTCOME DATA FROM SCOTTISH BOWEL SCREENING PROGRAMME. Annals of Oncology. I20-I20. 2010
- Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy. Blood. 566-566. 2009
- Determining Patterns of Therapy Choice in Patients Treated for Early Stage, Aggressive Histology Non-Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics. S484-S485. 2009
- 17 DETERMINING PATTERNS OF THERAPY CHOICE IN PATIENTS TREATED FOR EARLY STAGE, AGGRESSIVE HISTOLOGY NONHODGKIN'S LYMPHOMA. Radiotherapy and Oncology. S6-S6. 2009
- From macrocyclic libraries to the clinic: Discovery of ulimorelin (TZP-101). ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2009
- Large-Scale Production of Autologous CD14+-Monocyte Derived Dendritic Cells Co-Electroporated with Amplified Total Tumour mRNA and Human CD40L mRNA in Patients with B-Cell Chronic Lymphocytic Leukemia.. Blood. 3720-3720. 2006
- MEDI 424-Potent, macrocyclic motilin receptor antagonists incorporating new unnatural amino acids. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2006
- Misunderstanding of prostate cancer (CaP) among African American (AA) men of lower socioeconomic status (Lo-SES).. Journal of Clinical Oncology. 329S-329S. 2006
- The Effect of Prophylactic Administration of Myeloid Growth Factors Following Autologous Stem Cell Transplantation for Patients with Hematological Malignancies: A Systematic Review.. Blood. 2192-2192. 2004
- The Use of Aprotinin to Reduce Transfusion Requirements in Children Undergoing Cardiac Surgery: A Meta-Analysis.. Blood. 2718-2718. 2004
- Induction of specific immunity to B-CLL cells by in vitro stimulation using antigen pulsed autologous dendritic cells.. Blood. 439A-439A. 2003
- The ability to harvest increased numbers of peripheral blood progenitor cells is a predictor of improved overall survival in patients with multiple myeloma treated by autologous hematopoietic stem cell transplantation. Blood. 983A-983A. 2003
- A case-control study of screening colonoscopy in relatives of colorectal cancer patients. Gastroenterology. A484-A484. 2002
- Diet and risk of fatal ovarian cancer among Seventh-day Adventists women. The Adventists health study.. American Journal of Epidemiology. S197-S197. 2001
- Information needs of women at risk for hereditary breast cancer.. American Journal of Human Genetics. 206-206. 2000
- Attitudes about hereditary breast cancer among diverse breast cancer survivors.. American Journal of Human Genetics. A82-A82. 1999
- Effect of nutritional and clinical factors on serum prostate specific antigen and prostate cancer in a population of elderly California men. American Journal of Clinical Nutrition. 623S-623S. 1999
- Vitamin D serum levels in different Dukes' stages of colorectal cancer. Gut. A249-A249. 1997
- Colorectal cancer in the south of Israel: Comparison of the clinical characteristics and survival of two periods, 1981-2 and 1986-7.. Gastroenterology. A600-A600. 1997
- Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells. Gastroenterology. A591-A591. 1996
- DOES THE ADDITION OF CHEMOTHERAPY TO RADIOTHERAPY IMPROVE SURVIVAL IN ADVANCED HEAD AND NECK-CANCER. Clinical Otolaryngology. 284-284. 1982
-
journal articles
- Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy. BMC Cancer. 24:984. 2024
- COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies. Vaccine. S0264-410X(24)00715-1. 2024
-
Canadian cancer trials group
LY .17: A randomized phaseII study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP ) versus R‐GDP . British Journal of Haematology. 2024 - Abstract 3233: EP102: Pharmacological Inhibition of METTL3 causes tumor growth inhibition and prolongs survival in preclinical models of NSCLC, ovarian and squamous cell carcinoma. Cancer Research. 84:3233-3233. 2024
- Fractionated Stereotactic Radiation for Central Nervous System Lymphoma: Retrospective Analysis of Initial Cases. Current Oncology. 30:8602-8611. 2023
- Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials. Hematological Oncology. 41:461-463. 2023
- Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease. Molecular Therapy - Methods and Clinical Development. 28:262-271. 2023
- Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas. Blood. 140:8036-8037. 2022
- What do hematology residents know about caring for older adults with cancer? A national survey of Canadian hematology residents' knowledge and interests. Journal of Geriatric Oncology. 13:1236-1240. 2022
- A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 21:766-774. 2021
- Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. Current Oncology Reports. 23:113. 2021
- Lentivirus-mediated gene therapy for Fabry disease. Nature Communications. 12:1178. 2021
- First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma. Current Oncology. 27:632-644. 2020
- First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma.. Current Oncology. 27:632-644. 2020
- A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia. Blood. 136:27-30. 2020
- Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia. 19:715-722.e6. 2019
- MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins. Clinical Oncology. 31:479-485. 2019
- Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Pharmaceutical Research. 36:93. 2019
- PS1161 EFFICACY AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PREVIOUSLY TREATED WITH VENETOCLAX IN THE MURANO STUDY. HemaSphere. 3:527-527. 2019
- Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 33:969-980. 2019
- Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. British Journal of Haematology. 184:558-569. 2019
- Canadian Evidence-Based Guideline for the First-Line Treatment of Chronic Lymphocytic Leukemia. Current Oncology. 25:461-474. 2018
- Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. 18:648-657.e15. 2018
- Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. Leukemia and Lymphoma. 59:2075-2084. 2018
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Hematology Journal. 102:1796-1805. 2017
- Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Cancer Research. 77:CT158-CT158. 2017
- The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leukemia and Lymphoma. 58:1358-1365. 2017
- CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP. Hematological Oncology. 35:88-88. 2017
- IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL. Hematological Oncology. 35:232-233. 2017
- INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS. Hematological Oncology. 35:109-111. 2017
- Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Advances. 1:772-778. 2017
- Examining the Medical Resource Utilization and Costs of Relapsed and Refractory Chronic Lymphocytic Leukemia in Ontario. Current Oncology. 24:50-54. 2017
- CARDIOVASCULAR COMPLICATIONS OF IBRUTINIB: A SYSTEMATIC REVIEW AND META-ANALYSIS. Canadian Journal of Cardiology. 32:S272-S272. 2016
- Follow-Up Care for Survivors of Lymphoma Who Have Received Curative-Intent Treatment. Current Oncology. 23:499-513. 2016
- Multiple Myeloma Mortality in Relation to Obesity Among African Americans. Journal of the National Cancer Institute. 108:djw120-djw120. 2016
- The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 128:138-140. 2016
- Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leukemia and Lymphoma. 57:1291-1299. 2016
- Accrual of Adolescents and Young Adults with Cancer to Clinical Trials. Current Oncology. 23:81-85. 2016
- Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal. 6:e404-e404. 2016
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. The Lancet Oncology. 17:200-211. 2016
- Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. Clinical Lymphoma, Myeloma and Leukemia. 16:18-28.e4. 2016
- Are strict vegetarians protected against prostate cancer?. American Journal of Clinical Nutrition. 103:153-160. 2016
- Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Annals of Oncology. 26:2257-2266. 2015
- Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.. Journal of Clinical Oncology. 33:LBA7005-LBA7005. 2015
- A randomized, open‐label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 167:466-477. 2014
- Identifying the supportive care needs of adolescent and young adult survivors of cancer: a qualitative analysis and systematic literature review. Supportive Care in Cancer. 22:947-959. 2014
- Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario.. Journal of Clinical Oncology. 31:e17525-e17525. 2013
- Vegetarian Diets and the Incidence of Cancer in a Low-risk Population. Cancer Epidemiology, Biomarkers and Prevention. 22:286-294. 2013
- Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). Blood. 120:3925-3925. 2012
- Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non−Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. Blood. 118:2091-2091. 2011
- Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study). Blood. 118:2859-2859. 2011
- Foods and Food Groups Associated With the Incidence of Colorectal Polyps: The Adventist Health Study. Nutrition and Cancer. 63:565-572. 2011
- Principles and Recommendations for the Provision of Healthcare in Canada to Adolescent and Young Adult–Aged Cancer Patients and Survivors. Journal of Adolescent and Young Adult Oncology. 1:53-59. 2011
- The Frequency and Clinical Significance of Thrombocytopenia Complicating Critical Illness. Chest. 139:271-278. 2011
- The Frequency and Clinical Significance of Thrombocytopenia Complicating Critical Illness: A Systematic Review. Blood. 116:4664-4664. 2010
- Biological Diversity from a Structurally Diverse Library: Systematically Scanning Conformational Space Using a Pyranose Scaffold. Journal of Medicinal Chemistry. 53:5576-5586. 2010
- Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy.. Blood. 114:1390-1390. 2009
- Still No Meta-Analysis of Screening Colonoscopy for Colorectal Cancer? Reply. Digestive Diseases and Sciences. 54:697-697. 2009
- Analysis of the Clinical Impact of the Use of Palifermin in Patients Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma and Relapsed Lymphoma. Blood. 112:4332-4332. 2008
- Biomarkers and the Design of Clinical Trials in Cancer. Biomarkers in Medicine. 1:387-397. 2007
- Alemtuzumab in Chronic Lymphocytic Leukemia. Current Oncology. 14:96-109. 2007
- Generation ofin vitroB-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate. Leukemia and Lymphoma. 47:297-306. 2006
- Locally advanced breast cancer in octogenarian women. Breast Cancer Research and Treatment. 89:81-90. 2005
- Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Transplantation and Cellular Therapy. 10:287-297. 2004
- Case-control study of screening colonoscopy in relatives of patients with colorectal cancer. American Journal of Gastroenterology. 98:486-489. 2003
- Protective effect of faecal occult blood test screening for colorectal cancer: worse prognosis for screening refusers. Gut. 50:33-37. 2002
- Extraosseous Osteosarcoma of the Penis. Clinical Oncology. 12:238-239. 2000
- Extraosseous Osteosarcoma of the Penis. Clinical Oncology. 12:238-239. 2000
- Long-term survival following extra-neural metastasis from a pineoblastoma.. Journal of Neuro-Oncology. 48:141-144. 2000
- Mothers and daughters from breast cancer families: a qualitative study of their perceptions of risks and benefits associated with minor's participation in genetic susceptibility research.. Journal of the American Medical Women's Association. 55:280-293. 2000
- Metastatic Breast Cancer Presenting as Tolosa–Hunt Syndrome. Clinical Oncology. 11:407-409. 1999
- Occupational physical activity and risk of cancer of the colon and rectum in New Zealand males. Cancer Causes and Control. 4:45-50. 1993
-
preprints